Literature DB >> 27826031

TLR signalling and association of TLR polymorphism with cardiovascular diseases.

Swati Sharma1, Iti Garg2, Mohammad Z Ashraf1.   

Abstract

Toll-Like receptors (TLRs) are the primary receptors of innate immunity. Considerable evidences have shown that innate immune defence interaction with pro-inflammatory pathways could be through TLRs that in turn leads to development of inflammatory diseases. These TLRs are present on various tissues and cells of cardiovascular system. Previous studies involving SNPs analysis of TLRs demonstrated that TLRs are involved in development and progression of diseases like atherosclerosis, cardiac dysfunction in sepsis and congestive heart failure. In this review, we aimed to bring together the studies which have been conducted previously to establish a link between TLR polymorphism in context to development of cardiovascular diseases (CVD).
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular diseases; TLR polymorphism; Toll-like receptors (TLRs)

Mesh:

Substances:

Year:  2016        PMID: 27826031     DOI: 10.1016/j.vph.2016.10.008

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  12 in total

Review 1.  Toll-Like Receptors Contribute to Sex Differences in Blood Pressure Regulation.

Authors:  Vanessa Dela Justina; Fernanda R Giachini; Jennifer C Sullivan; R Clinton Webb
Journal:  J Cardiovasc Pharmacol       Date:  2020-09       Impact factor: 3.105

Review 2.  Immunostimulatory biomaterials to boost tumor immunogenicity.

Authors:  Oluwaseyi T Shofolawe-Bakare; Larry D Stokes; Mehjabeen Hossain; Adam E Smith; Thomas A Werfel
Journal:  Biomater Sci       Date:  2020-09-02       Impact factor: 6.843

Review 3.  Linkage of Infection to Adverse Systemic Complications: Periodontal Disease, Toll-Like Receptors, and Other Pattern Recognition Systems.

Authors:  Shannon M Wallet; Vishwajeet Puri; Frank C Gibson
Journal:  Vaccines (Basel)       Date:  2018-04-05

Review 4.  Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.

Authors:  Kumar Vijay
Journal:  Int Immunopharmacol       Date:  2018-05-04       Impact factor: 4.932

Review 5.  Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis.

Authors:  Ai-Fang Feng; Zhong-Hui Liu; Shu-Long Zhou; Shi-Yuan Zhao; Yan-Xin Zhu; Huai-Xin Wang
Journal:  BMC Cardiovasc Disord       Date:  2017-07-03       Impact factor: 2.298

Review 6.  Online Databases and Non-coding RNAs in Cardiovascular Diseases.

Authors:  Rui Chen; Chao Shi; Jianhua Yao; Wei Chen
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure.

Authors:  Xiaoping Wang; Dongqing Guo; Weili Li; Qian Zhang; Yanyan Jiang; Qiyan Wang; Chun Li; Qi Qiu; Yong Wang
Journal:  J Cell Mol Med       Date:  2020-08-05       Impact factor: 5.310

Review 8.  Modulations of Cardiac Functions and Pathogenesis by Reactive Oxygen Species and Natural Antioxidants.

Authors:  Sun-Hee Woo; Joon-Chul Kim; Nipa Eslenur; Tran Nguyet Trinh; Long Nguyen Hoàng Do
Journal:  Antioxidants (Basel)       Date:  2021-05-11

9.  The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions.

Authors:  Iván Parra-Izquierdo; Hari Hara Sudhan Lakshmanan; Alexander R Melrose; Jiaqing Pang; Tony J Zheng; Kelley R Jordan; Stéphanie E Reitsma; Owen J T McCarty; Joseph E Aslan
Journal:  Front Immunol       Date:  2021-08-30       Impact factor: 7.561

Review 10.  Research progress on Toll-like receptor signal transduction and its roles in antimicrobial immune responses.

Authors:  Pengpeng Xia; Yunping Wu; Siqi Lian; Li Yan; Xia Meng; Qiangde Duan; Guoqiang Zhu
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-28       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.